contd U2

nicotinic acetylcholine activating effective amount of a compound as claimed in claim 9 or pharmaceutically acceptable salts thereof.--

## REMARKS

It is respectfully requested that the above amendments be entered prior to calculation of the filing fee and prior to examination. The claims have been amended to correct improper numbering and to place them in better form for U.S. practice. No new matter has been added.

If there are any questions regarding this amendment or the application in general, a telephone call to the undersigned would be appreciated since this should expedite the prosecution of the application for all concerned.

Respe

August 22, 2001

Herbert I. Cantor

Registration No. 24,392

CROWELL & MORING, LLP P.O. Box 14300 Washington, DC 20044-4300

Telephone No.: (202) 628-8800

Facsimile No.: (202) 628-8844

## APPENDIX

Please amend Claim 8 as follows:

--8. (Amended) [The use of the compounds] A method of activating  $\alpha 4\beta 2$  nicotinic acetylcholine receptors comprising administering an  $\alpha 4\beta 2$  nicotinic acetylcholine activating effective amount of a compound as claimed in claim 1 or pharmaceutically acceptable salts thereof [as the activators for  $\alpha 4\beta 2$  nicotinic acetylcholine receptors].--

Please amend the second Claim 8 appearing on page 58 as follows:

[8] 17. (Amended) [The use of the compounds] A method of activating  $\alpha 4\beta 2$  nicotinic acetylcholine receptors comprising administering an  $\alpha 4\beta 2$  nicotinic acetylcholine activating effective amount of a compound as claimed in claim 9 or pharmaceutically acceptable salts thereof [as the activators for  $\alpha 4\beta 2$  nicotinic acetylcholine receptors].--